当前位置: 首页 >> 检索结果
41. Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis.
作者: W H Wilson Tang.;Yuxi Liu.;Javed Butler.;Stefano Del Prato.;Justin A Ezekowitz.;Nasrien E Ibrahim.;Carolyn S P Lam.;Thomas H Marwick.;Riccardo Perfetti.;Julio Rosenstock.;Scott D Solomon.;Faiez Zannad.;James L Januzzi.;Gregory D Lewis.
来源: Circ Heart Fail. 2025年18卷3期e012200页
Objective indices of functional capacity in patients with diabetic cardiomyopathy and stage B heart failure (HF) have not been comprehensively defined. We sought to characterize the cardiopulmonary exercise characteristics of individuals with diabetic cardiomyopathy at high risk for overt HF.
42. Three-Dimensional CT for Preprocedural Planning of PCI for Ostial Right Coronary Artery Lesions: A Randomized Controlled Pilot Trial.
作者: Deborah M F van den Buijs.;Ella M Poels.;Endry Willems.;Daan Cottens.;Kevin Dotremont.;Karen De Leener.;Evelyne Meekers.;Bert Ferdinande.;Mathias Vrolix.;Joseph Dens.;Koen Ameloot.
来源: Circ Cardiovasc Interv. 2025年18卷2期e013584页
Geographic stent-ostium mismatch is an important predictor of target lesion failure after percutaneous coronary intervention of an aorto-ostial right coronary artery lesion. Optimal visualization of the aorto-ostial plane is crucial for precise stent implantation at the level of the ostium. This study investigates whether preprocedural 3-dimensional computed tomography (3DCT), with determination of the optimal viewing angle, would allow for more precise stent implantation and reduce procedure time, contrast, and radiation dose.
43. Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial.
作者: Stefano Barco.;Houman Jalaie.;Tim Sebastian.;Simon Wolf.;Riccardo M Fumagalli.;Michael Lichtenberg.;Thomas Zeller.;Christian Erbel.;Oliver Schlager.;Nils Kucher.
来源: Circulation. 2025年151卷12期835-846页
In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial (Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS) tested whether 100 mg of daily aspirin plus 20 mg of rivaroxaban is superior to 20 mg of rivaroxaban alone to prevent stent thrombosis within 6 months after stent placement for post-thrombotic syndrome.
44. Optimal Predilatation Treatment Before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis: The OPTIMIS Trial.
作者: Kirstine Nørregaard Hansen.;Jens Trøan.;Akiko Maehara.;Manijeh Noori.;Mikkel Hougaard.;Julia Ellert-Gregersen.;Karsten Tange Veien.;Anders Junker.;Henrik Steen Hansen.;Jens Flensted Lassen.;Lisette Okkels Jensen.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014665页
Bioresorbable scaffolds (BRS) were developed to overcome limitations related to late stent failures of drug-eluting stents, but lumen reductions over time after implantation of BRS have been reported. This study aimed to investigate if lesion preparation with a scoring balloon compared with a standard noncompliant balloon minimizes lumen reduction after implantation of a Magmaris BRS assessed with optical coherence tomography and intravascular ultrasound.
45. Impact of Bifurcation Lesions on Outcomes After FFR-Guided PCI or CABG.
作者: Daimy M M Dillen.;Hisao Otsuki.;Kuniaki Takahashi.;Yuhei Kobayashi.;Zsolt Piroth.;Nicolas Noiseux.;Badih El Nakadi.;Gintaras Kalinauskas.;Laszlo Szekely.;Giedrius Davidavičius.;Koen Teeuwen.;Pim A L Tonino.;Nico H J Pijls.;Bernard De Bruyne.;William F Fearon.;Frederik M Zimmermann.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014610页
In the era of first-generation drug-eluting stents and angiography-guided percutaneous coronary intervention (PCI), the presence of a bifurcation lesion was associated with adverse outcomes after PCI. In contrast, the presence of a bifurcation lesion had no impact on outcomes following coronary artery bypass grafting (CABG). Therefore, the presence of a coronary bifurcation lesion requires special attention when choosing between CABG and PCI. The aim of this study is to assess whether the presence of a bifurcation lesion still influences clinical outcomes after contemporary PCI using second-generation drug-eluting stent and fractional flow reserve (FFR) guidance versus CABG.
46. Cryoballoon Pulmonary Vein Isolation With Versus Without Additional Right Atrial Linear Ablation for Persistent Atrial Fibrillation: The CRALAL Randomized Clinical Trial.
作者: Daehoon Kim.;Hee Tae Yu.;Jaemin Shim.;Junbeom Park.;Yong-Soo Baek.;Sang Won Park.;Dae-Kyeong Kim.;Young-Ah Park.;Tae-Hoon Kim.;Jae-Sun Uhm.;Boyoung Joung.;Moon-Hyoung Lee.;Hui-Nam Pak.
来源: Circ Arrhythm Electrophysiol. 2025年18卷1期e013408页
Pulmonary vein isolation (PVI) alone is less effective in patients with persistent atrial fibrillation (AF) compared with those with paroxysmal AF. We investigate whether additional linear ablation from the superior vena cava to the right atrial septum and cavotricuspid isthmus ablation improves the rhythm outcome of patients with persistent AF undergoing cryoballoon PVI (Cryo-PVI).
47. Nurse-Led Multicomponent Behavioral Activation Intervention for Patients With Atrial Fibrillation: A Randomized Controlled Trial.
Patients with atrial fibrillation (AF) are often ill-equipped for shared decision-making. This study investigated the effects of a patient empowerment care model on patient-reported health outcomes and treatment decision-making in patients with AF.
48. Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2.
作者: Kevin R Bainey.;Robert C Welsh.;Yinggan Zheng.;Alexandra Arias-Mendoza.;Arsen D Ristic.;Oleg V Averkov.;Yves Lambert.;José F Kerr Saraiva.;Pablo Sepulveda.;Fernando Rosell-Ortiz.;John K French.;Ljilja B Musić.;Tracy Temple.;Eric Ly.;Kris Bogaerts.;Peter R Sinnaeve.;Thierry Danays.;Cynthia M Westerhout.;Frans Van de Werf.;Paul W Armstrong.; .
来源: Circ Cardiovasc Interv. 2024年17卷12期e014251页
In STREAM-1 (Strategic Reperfusion Early After Myocardial Infarction), excess intracranial hemorrhage occurred in patients aged ≥75 years receiving full-dose tenecteplase as part of a pharmaco-invasive strategy, whereas no further intracranial hemorrhage occurred after halving the tenecteplase dose. In STREAM-2 (Second Strategic Reperfusion Early After Myocardial Infarction), half-dose tenecteplase was an effective and safe pharmaco-invasive strategy in older patients with ST-segment-elevation myocardial infarction presenting within <3 hours, compared with primary percutaneous coronary intervention (PCI). We prespecified evaluating the efficacy and safety of a half-dose versus full-dose pharmaco-invasive strategy and compared the half-dose pharmaco-invasive strategy to primary PCI in patients aged ≥75 years.
49. Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial.
作者: Harmony R Reynolds.;Courtney B Page.;Leslee J Shaw.;Daniel S Berman.;Bernard R Chaitman.;Michael H Picard.;Raymond Y Kwong.;James K Min.;Jonathon Leipsic.;G B John Mancini.;Matthew J Budoff.;Cameron J Hague.;Roxy Senior.;Hanna Szwed.;Balram Bhargava.;Jelena Celutkiene.;Milind Gadkari.;Kevin R Bainey.;Rolf Doerr.;Ruben B Ramos.;Peter Ong.;Sudhir R Naik.;Philippe Gabriel Steg.;Kaatje Goetschalckx.;Benjamin J W Chow.;Marielle Scherrer-Crosbie.;Lawrence Phillips.;Daniel B Mark.;John A Spertus.;Karen P Alexander.;Sean M O'Brien.;William E Boden.;Sripal Bangalore.;Gregg W Stone.;David J Maron.;Judith S Hochman.; .
来源: Circ Cardiovasc Interv. 2024年17卷12期e013743页
The relationship between the extent and severity of stress-induced ischemia and the extent and severity of anatomic coronary artery disease (CAD) in patients with obstructive CAD is multifactorial and includes the intensity of stress achieved, type of testing used, presence and extent of prior infarction, collateral blood flow, plaque characteristics, microvascular disease, coronary vasomotor tone, and genetic factors. Among chronic coronary disease participants with site-determined moderate or severe ischemia, we investigated associations between ischemia severity on stress testing and the extent of CAD on coronary computed tomography angiography.
50. Superior Vena Cava Isolation With Cryoballoon in AF Ablation: Randomized CAVAC AF Trial.
作者: Víctor Castro-Urda.;Melodie Segura-Dominguez.;Diego Jiménez-Sánchez.;Cristina Aguilera-Agudo.;Paula Vela-Martín.;Alvaro Lorente-Ros.;Daniel García-Rodriguez.;David Sánchez-Ortiz.;Chinh Pham-Trung.;Eusebio García-Izquierdo.;Susana Mingo-Santos.;Jorge Toquero-Ramos.;Ignacio Fernández-Lozano.
来源: Circ Arrhythm Electrophysiol. 2025年18卷1期e012917页
Superior vena cava (SVC) has been considered a specific trigger in atrial fibrillation development.
51. Inappropriate Therapy and Shock Rates Between the Subcutaneous and Transvenous Implantable Cardiac Defibrillator: A Secondary Analysis of the PRAETORIAN Trial.
作者: Louise R A Olde Nordkamp.;Shari Pepplinkhuizen.;Abdul Ghani.;Lucas V A Boersma.;Juergen Kuschyk.;Mikhael F El-Chami.;Elijah R Behr.;Tom F Brouwer.;Stefan Kääb.;Suneet Mittal.;Anne-Floor B E Quast.;Willeke van der Stuijt.;Lonneke Smeding.;Jolien A de Veld.;Jan G P Tijssen.;Nick R Bijsterveld.;Sergio Richter.;Marc A Brouwer.;Joris R de Groot.;Kirsten M Kooiman.;Pier D Lambiase.;Petr Neuzil.;Kevin Vernooy.;Marco Alings.;Timothy R Betts.;Frank A L E Bracke.;Martin C Burke.;Jonas S S G de Jong.;David J Wright.;Ward P J Jansen.;Zachary I Whinnett.;Peter Nordbeck.;Michael Knaut.;Berit T Philbert.;Jurren M van Opstal.;Alexandru B Chicos.;Cornelis P Allaart.;Alida E Borger van der Burg.;Jose M Dizon.;Marc A Miller.;Dmitry Nemirovsky.;Ralf Surber.;Gaurav A Upadhyay.;Raul Weiss.;Anouk de Weger.;Arthur A M Wilde.;Reinoud E Knops.; .
来源: Circ Arrhythm Electrophysiol. 2024年17卷12期e012836页
Inappropriate therapy (IAT) is an undesirable side effect of implantable cardiac defibrillator (ICD) therapy. Early studies with the subcutaneous ICD (S-ICD) showed relatively high inappropriate shock (IAS) rates. The PRAETORIAN (Prospective Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) trial demonstrated that the S-ICD is noninferior to the transvenous ICD (TV-ICD) with regard to the combined end point of IAS and complications. This secondary analyses evaluates all IAT in the PRAETORIAN trial.
52. Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF).
作者: Neal W Dickert.;Candace D Speight.;Madeline Balser.;Henry Biermann.;J Kelly Davis.;Scott D Halpern.;Yi-An Ko.;Advaita Krishnan.;Daniel D Matlock.;Andrea R Mitchell.;Miranda A Moore.;Sarah C Montembeau.;Alanna A Morris.;Kathleen Noonan.;Birju R Rao.;Laura D Scherer.;Caroline E Sloan.;Peter A Ubel.;Larry A Allen.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷1期e011273页
Guideline-directed medical therapy for heart failure (HF) with reduced ejection fraction can entail high out-of-pocket (OOP) costs, prompting concerns about financial toxicity and access. OOP costs are generally unavailable during encounters. This trial assessed the impact of providing patient-specific OOP costs to patients and clinicians.
53. Comparison of Procedural Outcomes of Lumenless Fixed-Helix Versus Stylet-Driven Extendable-Helix Lead Systems in Left Bundle Branch Pacing: COMPARE LBBP.
作者: Jenish P Shroff.;Anugrah Nair.;Deep Chandh Raja.;Sreevilasam P Abhilash.;Simon Fiorese.;Jonathan P Ariyaratnam.;Walter P Abhayaratna.;Prashanthan Sanders.;Pugazhendhi Vijayaraman.;Rajeev K Pathak.
来源: Circ Arrhythm Electrophysiol. 2024年17卷12期e013385页
Left bundle branch pacing (LBBP) has emerged as a safe and effective alternative to right ventricular pacing. Traditionally, LBBP is performed with lumenless lead (LLL); however, the use of stylet-driven lead (SDL) is on rise. We aimed to assess acute success and procedural outcomes of SDL versus LLL for LBBP.
54. CTCA Prior to Invasive Coronary Angiography in Patients With Previous Bypass Surgery: Patient-Related Outcomes, Imaging Resource Utilization, and Cardiac Events at 3 Years From the BYPASS-CTCA Trial.
作者: Matthew Kelham.;Anne-Marie Beirne.;Krishnaraj S Rathod.;Mervyn Andiapen.;Lucinda Wynne.;Annastazia E Learoyd.;Nasim Forooghi.;Rohini Ramaseshan.;James C Moon.;Ceri Davies.;Christos V Bourantas.;Andreas Baumbach.;Charlotte Manisty.;Andrew Wragg.;Amrita Ahluwalia.;Francesca Pugliese.;Anthony Mathur.;Daniel A Jones.
来源: Circ Cardiovasc Interv. 2024年17卷12期e014142页
In patients with previous coronary artery bypass grafting, computed tomography cardiac angiography (CTCA) before invasive coronary angiography (ICA) was demonstrated in the BYPASS-CTCA trial (Randomized Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients) to reduce procedure time and incidence of contrast-associated acute kidney injury, with greater levels of patient satisfaction. Patient-related outcomes, utilization of further diagnostic imaging resources, and longer-term incidence of major adverse cardiac events were key secondary end points not yet reported.
55. Quantifying Pill Disutility Associated With Starting Versus Continuing Cardioprotective Medication: A Randomized Experiment.
作者: Alexander Chaitoff.;Julie C Lauffenburger.;Nancy Haff.;Katharina Tabea Jungo.;Niteesh K Choudhry.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷11期e011069页
Quantifying patient-reported pill disutility is important for understanding the risk-benefit tradeoffs of taking medications. The objective of this study was to quantify and compare the pill disutility associated with starting a new medication and continuing an existing medication for cardiometabolic disease prevention in a sample of older adults in the United States.
56. Quality of Life in Subcutaneous or Transvenous Implantable Cardioverter-Defibrillator Patients: A Secondary Analysis of the PRAETORIAN Trial.
作者: Reinoud E Knops.;Jolien A de Veld.;Abdul Ghani.;Lucas V A Boersma.;Juergen Kuschyk.;Mikhael F El Chami.;Hendrik Bonnemeier.;Elijah R Behr.;Tom F Brouwer.;Stefan Kääb.;Suneet Mittal.;Shari Pepplinkhuizen.;Anne-Floor B E Quast.;Lonneke Smeding.;Willeke van der Stuijt.;Anouk de Weger.;Nick R Bijsterveld.;Sergio Richter.;Marc A Brouwer.;Joris R de Groot.;Kirsten M Kooiman.;Pier D Lambiase.;Petr Neuzil.;Kevin Vernooy.;Marco Alings.;Timothy R Betts.;Frank A L E Bracke.;Martin C Burke.;Jonas S S G de Jong.;David J Wright.;Ward P J Jansen.;Zachary I Whinnett.;Peter Nordbeck.;Michael Knaut.;Berit T Philbert.;Jurren M van Opstal.;Alexandru B Chicos.;Cornelis P Allaart.;Alida E Borger van der Burg.;Jose M Dizon.;Marc A Miller.;Dmitry Nemirovksy.;Ralf Surber.;Gaurav A Upadhyay.;Jan G P Tijssen.;Arthur A M Wilde.;Louise R A Olde Nordkamp.; .
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷11期e010822页
The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to overcome the risk of lead-related complications associated with the transvenous implantable cardioverter-defibrillator (TV-ICD). In contrast to the TV-ICD, the S-ICD is a completely extrathoracic device. Subsequently, complications differ between these 2 implantable cardioverter-defibrillators, which might impact patient perceptions of the therapies. This prespecified secondary analysis of the PRAETORIAN trial evaluates differences in quality of life.
57. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab.
作者: Konstantinos C Koskinas.;Jonas Häner.;Yasushi Ueki.;Tatsuhiko Otsuka.;Jacob Lonborg.;Hiroki Shibutani.;Ryota Kakizaki.;Christoph Kaiser.;Robert-Jan van Geuns.;Anna S Ondracek.;Fabien Praz.;Maria Ambühl.;David Spirk.;Jonas Lanz.;Joost Daemen.;Dik Heg.;Manuel Mayr.;François Mach.;Stephan Windecker.;Thomas Engstrøm.;Irene M Lang.;Arnold von Eckardstein.;Sylvain Losdat.;Lorenz Räber.
来源: Circ Cardiovasc Imaging. 2024年17卷11期e016683页
Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy.
58. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
作者: Michael R Zile.;Barry A Borlaug.;Christopher M Kramer.;Seth J Baum.;Sheldon E Litwin.;Venu Menon.;Yang Ou.;Govinda J Weerakkody.;Karla C Hurt.;Chisom Kanu.;Masahiro Murakami.;Milton Packer.; .
来源: Circulation. 2025年151卷10期656-668页
Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients.
59. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
作者: Daniel P Judge.;Julian D Gillmore.;Kevin M Alexander.;Amrut V Ambardekar.;Francesco Cappelli.;Marianna Fontana.;Pablo García-Pavía.;Justin L Grodin.;Martha Grogan.;Mazen Hanna.;Ahmad Masri.;Jose Nativi-Nicolau.;Laura Obici.;Steen Hvitfeldt Poulsen.;Nitasha Sarswat.;Keyur Shah.;Prem Soman.;Ted Lystig.;Xiaofan Cao.;Kevin Wang.;Maria Lucia Pecoraro.;Jean-François Tamby.;Leonid Katz.;Uma Sinha.;Jonathan C Fox.;Mathew S Maurer.
来源: Circulation. 2025年151卷9期601-611页
In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE.
60. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
作者: Milind Y Desai.;Kathy Wolski.;Anjali Owens.;Jeffrey B Geske.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Paul C Cremer.;Neal K Lakdawala.;Albree Tower-Rader.;David Fermin.;Srihari S Naidu.;Nicholas G Smedira.;Hartzell Schaff.;Zhiqun Gong.;Lana Mudarris.;Kathy Lampl.;Amy J Sehnert.;Steven E Nissen.; .
来源: Circulation. 2025年151卷19期1378-1390页
In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128.
|